Sevdenur Banu Yigit
Research Subjects
Sevdenur Banu Yigit has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ali Irfan Guzel
School of Medicine, Department of Obstetrics and Gynecology, Sanko University
1 shared publication - Ayse Nur Aksoy
University of Health Sciences, Türkiye
1 shared publication - Belgin Devranoglu
Assisted Reproductive Technology Unit, Department of Obstetrics and Gynecology, Zeynep Kâmil Women and Children’s Diseases Training and Research Hospital, University of Health Sciences, Istanbul 34668, Türkiye
1 shared publication - Esra Tustas Haberal
Hisar Hospital, 34768 Istanbul, Türkiye
1 shared publication - Habibe Ayvacı
Zeynep Kamil Women and Children's Diseases Training and Research Hospital İstanbul Türkiye
1 shared publication - Halise Hande Gezer
Rheumatology Division, Physical Medicine and Rehabilitation Department, Marmara University School of Medicine, Istanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
- 7 November 2026
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 28 (11)
Guideline Implementation Gap in Preeclampsia Prevention: Adherence to Low‐Dose Aspirin Use in Routine Obstetric Practice
Evidence‐based guidelines recommend the use of low‐dose aspirin (LDA) to prevent preeclampsia. Gaps between recommended and actual care may limit the impact of proven preventive interventions. This study aimed to assess obstetricians’ adherence to LDA prescription for preeclampsia prevention in accordance with the national guideline. This retrospective cohort study included 1150 women who delivered between November 2023 and December 2024. Eligibility for LDA use was determined according to guideline‐defined risk criteria. Adherence was defined as prescribing LDA between 11 and 16 weeks of gestation. The rate of LDA recommendation was assessed and factors associated with LDA prescription were analyzed. 210 women (18.3%) met the criteria for LDA recommendation. However, LDA was prescribed to 97 (46.2%) of these women, indicating that more than half of the candidates missed the opportunity for prophylaxis. Among the 969 women who did not use LDA during pregnancy, 113 (11.7%) actually met the guideline criteria and should have received LDA. In this untreated group, the incidence of preeclampsia was approximately fourfold higher compared with women without an LDA indication (26.5% vs. 8.2%; OR 4.06, 95% CI 2.50–6.58, p < 0.001). Follow‐up at a tertiary healthcare center at or before 16 weeks of gestation was associated with significantly higher rates of appropriate LDA prescription ( p < 0.001). Adherence to national guideline for the prevention of preeclampsia remains suboptimal in Türkiye. This implementation gap represents missed opportunities for the prevention of preeclampsia and underscores the need for targeted educational initiatives and system‐level interventions.
- 7 November 2026
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 28 (11)
Open AccessGuideline Implementation Gap in Preeclampsia Prevention: Adherence to Low‐Dose Aspirin Use in Routine Obstetric Practice
Evidence‐based guidelines recommend the use of low‐dose aspirin (LDA) to prevent preeclampsia. Gaps between recommended and actual care may limit the impact of proven preventive interventions. This study aimed to assess obstetricians’ adherence to LDA prescription for preeclampsia prevention in accordance with the national guideline. This retrospective cohort study included 1150 women who delivered between November 2023 and December 2024. Eligibility for LDA use was determined according to guideline‐defined risk criteria. Adherence was defined as prescribing LDA between 11 and 16 weeks of gestation. The rate of LDA recommendation was assessed and factors associated with LDA prescription were analyzed. 210 women (18.3%) met the criteria for LDA recommendation. However, LDA was prescribed to 97 (46.2%) of these women, indicating that more than half of the candidates missed the opportunity for prophylaxis. Among the 969 women who did not use LDA during pregnancy, 113 (11.7%) actually met the guideline criteria and should have received LDA. In this untreated group, the incidence of preeclampsia was approximately fourfold higher compared with women without an LDA indication (26.5% vs. 8.2%; OR 4.06, 95% CI 2.50–6.58, p < 0.001). Follow‐up at a tertiary healthcare center at or before 16 weeks of gestation was associated with significantly higher rates of appropriate LDA prescription ( p < 0.001). Adherence to national guideline for the prevention of preeclampsia remains suboptimal in Türkiye. This implementation gap represents missed opportunities for the prevention of preeclampsia and underscores the need for targeted educational initiatives and system‐level interventions.
- Open Access
- 6 January 2026
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 8 (1) , 146-152
Psoriatic arthritis and pregnancy: maternal and neonatal outcomes in a clinical cohort
Aims: To evaluate obstetric and neonatal outcomes in women with psoriatic arthritis (PsA) by comparing pregnancies before and after diagnosis, as well as with healthy controls, with a focus on disease activity, treatment exposure, and flares Methods: This retrospective cross-sectional study included 227 pregnancies from 85 women with PsA and 100 pregnancies from 46 healthy controls. Maternal and neonatal outcomes were assessed, including preeclampsia, gestational hypertension, gestational diabetes, cesarean delivery, preterm birth, small for gestational age (SGA), congenital anomalies, and neonatal intensive care unit (NICU) admissions. Disease activity and flares during pregnancy were recorded. Logistic regression analyses were performed to identify predictors of composite adverse maternal and neonatal outcomes. Results: Among PsA pregnancies, 161 (71%) occurred before and 66 (29%) after diagnosis. Maternal age at conception was higher post-diagnosis, and these pregnancies showed increased rates of cesarean delivery (60.4% vs. 16.9% and 14.5%, p
- 6 January 2026
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 8 (1) , 146-152
Open AccessPsoriatic arthritis and pregnancy: maternal and neonatal outcomes in a clinical cohort
Aims: To evaluate obstetric and neonatal outcomes in women with psoriatic arthritis (PsA) by comparing pregnancies before and after diagnosis, as well as with healthy controls, with a focus on disease activity, treatment exposure, and flares Methods: This retrospective cross-sectional study included 227 pregnancies from 85 women with PsA and 100 pregnancies from 46 healthy controls. Maternal and neonatal outcomes were assessed, including preeclampsia, gestational hypertension, gestational diabetes, cesarean delivery, preterm birth, small for gestational age (SGA), congenital anomalies, and neonatal intensive care unit (NICU) admissions. Disease activity and flares during pregnancy were recorded. Logistic regression analyses were performed to identify predictors of composite adverse maternal and neonatal outcomes. Results: Among PsA pregnancies, 161 (71%) occurred before and 66 (29%) after diagnosis. Maternal age at conception was higher post-diagnosis, and these pregnancies showed increased rates of cesarean delivery (60.4% vs. 16.9% and 14.5%, p
- Open Access
GnRHa Triggering Versus hCG Triggering in PCOS Patients Who Undergo Fresh or FET Cycles: Is the King Fake or Real?
Background and Objectives: To evaluate the impact of gonadotropin-releasing hormone agonist (GnRHa) triggering compared to human chorionic gonadotropin (hCG) triggering on frozen–thawed and fresh embryo transfer outcomes in patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF). Materials and Methods: This retrospective cohort study analyzed 267 IVF cycles of 261 PCOS patients treated with GnRH antagonist protocols. Patients were divided into three groups: GnRHa-triggered frozen–thawed embryo transfer (ET) (n = 126), hCG-triggered frozen–thawed ET (n = 68), and hCG-triggered fresh ET (n = 73). Baseline characteristics, stimulation parameters, and cycle outcomes were compared between groups. A binary logistic regression analysis was established to identify independent predictors of clinical pregnancy. Results: The GnRHa-triggered group had significantly higher numbers of retrieved oocytes, mature (MII) oocytes, and fertilized oocytes compared to both hCG-triggered groups (p < 0.001). The number of obtained embryos and frozen embryos (good-quality embryos) was highest in the GnRHa group (p < 0.001). However, clinical pregnancy rates were comparable between the groups with a similar number and grade of transferred embryos (32.53%, 38.23%, and 32.87%, respectively). Multivariate regression analysis revealed that the grade of the transferred embryo was a significant predictor of clinical pregnancy (p = 0.034). Conclusions: This study provides insights into different triggering strategies for final oocyte maturation in PCOS patients. GnRH-agonist-triggered frozen–thawed cycles showed comparable clinical pregnancy outcomes to those of hCG-triggered cycles, with a potentially lower OHSS risk. The findings suggest that individualized triggering approaches based on patient characteristics and OHSS risk may be beneficial for PCOS patients undergoing IVF.
Open AccessGnRHa Triggering Versus hCG Triggering in PCOS Patients Who Undergo Fresh or FET Cycles: Is the King Fake or Real?
Background and Objectives: To evaluate the impact of gonadotropin-releasing hormone agonist (GnRHa) triggering compared to human chorionic gonadotropin (hCG) triggering on frozen–thawed and fresh embryo transfer outcomes in patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF). Materials and Methods: This retrospective cohort study analyzed 267 IVF cycles of 261 PCOS patients treated with GnRH antagonist protocols. Patients were divided into three groups: GnRHa-triggered frozen–thawed embryo transfer (ET) (n = 126), hCG-triggered frozen–thawed ET (n = 68), and hCG-triggered fresh ET (n = 73). Baseline characteristics, stimulation parameters, and cycle outcomes were compared between groups. A binary logistic regression analysis was established to identify independent predictors of clinical pregnancy. Results: The GnRHa-triggered group had significantly higher numbers of retrieved oocytes, mature (MII) oocytes, and fertilized oocytes compared to both hCG-triggered groups (p < 0.001). The number of obtained embryos and frozen embryos (good-quality embryos) was highest in the GnRHa group (p < 0.001). However, clinical pregnancy rates were comparable between the groups with a similar number and grade of transferred embryos (32.53%, 38.23%, and 32.87%, respectively). Multivariate regression analysis revealed that the grade of the transferred embryo was a significant predictor of clinical pregnancy (p = 0.034). Conclusions: This study provides insights into different triggering strategies for final oocyte maturation in PCOS patients. GnRH-agonist-triggered frozen–thawed cycles showed comparable clinical pregnancy outcomes to those of hCG-triggered cycles, with a potentially lower OHSS risk. The findings suggest that individualized triggering approaches based on patient characteristics and OHSS risk may be beneficial for PCOS patients undergoing IVF.